Does Ozempic (Semaglutide) Cause Erectile Dysfunction?

Does Ozempic cause erectile dysfunction? The honest answer is that there is no good evidence that semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound) directly causes ED. Erectile dysfunction is not a listed adverse reaction in the FDA prescribing information for any of these drugs, and the pivotal weight-loss and diabetes trials did not flag an erectile-function signal. The far better-supported direction is the opposite one: because these drugs drive substantial weight loss, they tend to improve erectile function over time — obesity is one of the strongest modifiable causes of ED, and reversing it restores endothelial function and (in men) raises testosterone. That said, the searcher's experience deserves a fair hearing. A handful of plausible, mostly transient or indirect mechanisms — a deep caloric deficit, fatigue during dose escalation, dehydration, very rapid fat loss transiently shifting hormones, and the psychological load of a major body change — can dent erections or libido during the early weeks. The key distinction is between “directly caused by the drug” (no evidence) and “things that can happen during a weight-loss phase” (plausible, usually temporary). And because ED can be an early marker of cardiovascular disease, new ED is always worth a proper workup — not an assumption that “it must be the Ozempic.”

The honest summary

• ED is not a labeled side effect of any GLP-1. The FDA prescribing information (DailyMed) for Ozempic and Wegovy (semaglutide) and Mounjaro and Zepbound (tirzepatide) does not list erectile dysfunction as an adverse reaction. The common adverse effects are gastrointestinal (nausea, vomiting, diarrhea, constipation). No pivotal trial reported an ED signal.
• The stronger, evidence-backed direction is improvement. Obesity is a major modifiable cause of ED (Pizzol 2020^[9], Feldman 1994 Massachusetts Male Aging Study^[2]). Weight loss reverses obesity-driven ED (Esposito 2004 JAMA, mean IIEF 13.9→17.0^[1]) by restoring endothelial function (Khoo 2014^[6]) and raising testosterone as SHBG normalizes (Corona 2013 meta^[3], Camacho 2013 EMAS^[7]).
• GLP-1 weight loss is large. STEP-1 semaglutide produced −14.9% body weight^[4] and SURMOUNT-1 tirzepatide produced −20.9%^[5] — magnitudes that meet or exceed the Esposito lifestyle intervention that reversed ED. The expected long-run effect on erections in obesity-driven ED is positive, not negative.
• But indirect, usually transient dips are plausible. A deep caloric deficit, fatigue during titration, dehydration, very rapid fat loss transiently moving hormones, and the psychological load of a major body change can each blunt erections or libido early. The CALERIE 2 calorie-restriction RCT (Martin 2016^[8]) shows the deficit itself — independent of any drug — can affect sexual function.
• New ED can signal something else. Erectile dysfunction is an early marker of cardiovascular disease (Thompson 2005 JAMA^[10], Vlachopoulos 2013 meta^[11]). New or progressive ED warrants a workup — cardiovascular risk, testosterone, medications, mood, sleep — rather than blaming the GLP-1.

What the labels actually say

For all four brands in this question, erectile dysfunction is not a listed adverse reaction. The FDA-approved prescribing information (available on DailyMed and the manufacturer labels) describes the common adverse effects of semaglutide and tirzepatide as predominantly gastrointestinal: nausea, vomiting, diarrhea, constipation, and abdominal pain, most prominent during dose escalation. Labeled warnings center on thyroid C-cell tumors (boxed warning), pancreatitis, gallbladder disease, hypoglycemia when combined with insulin or sulfonylureas, diabetic retinopathy complications (semaglutide), and acute kidney injury from dehydration. Erectile dysfunction, decreased libido, and sexual dysfunction are not among the adverse reactions enumerated for Ozempic, Wegovy, Mounjaro, or Zepbound.

That matters because adverse-reaction tables in modern label documents are built from the pooled, placebo-controlled pivotal trials — tens of thousands of participants in the semaglutide and tirzepatide programs. If a drug were directly causing erectile dysfunction at any meaningful rate, it would typically surface as an imbalance versus placebo and be listed. It is not. (This is a regulatory-document fact, cited here from the prescribing information rather than from a PubMed-indexed study.)

Ozempic and Wegovy (semaglutide)

Ozempic and Wegovy are the same molecule, semaglutide, at type-2-diabetes and weight-management dosing respectively. Neither label lists erectile dysfunction. In STEP-1, semaglutide 2.4 mg weekly produced mean −14.9% body weight at 68 weeks^[4] — a magnitude that meets or exceeds the −13% to −15% lifestyle weight loss that reversed erectile dysfunction in roughly a third of obese men in the Esposito 2004 JAMA randomized trial^[1]. So the directionally honest expectation for a man with obesity-driven ED who loses meaningful weight on semaglutide is neutral-to-improved erectile function over months, not worsening. The same vascular and hormonal machinery that Esposito and Khoo documented (endothelial nitric-oxide recovery, falling inflammatory cytokines, rising free testosterone) is what semaglutide-driven weight loss engages. Our companion review of GLP-1 weight loss and ED reversal walks through the magnitude in detail.

Mounjaro and Zepbound (tirzepatide)

Mounjaro and Zepbound are both tirzepatide, the dual GIP/GLP-1 receptor agonist, at diabetes and weight-management dosing. As with semaglutide, erectile dysfunction is not a labeled adverse reaction. Tirzepatide produces the largest non-surgical weight loss seen to date: SURMOUNT-1 reported mean −20.9% body weight at 72 weeks on the 15 mg dose^[5]. That magnitude sits between the Esposito lifestyle intervention and bariatric surgery on the established weight-loss-to-erectile-function dose response — again pointing toward improvement rather than harm in obesity-driven ED. There is no published trial in which tirzepatide caused erectile dysfunction, and no mechanism by which GIP/GLP-1 receptor agonism would be expected to impair the cavernosal vascular response.

Why some men still notice ED on a GLP-1

Anecdotal reports — on Reddit and in forums — of erections or libido dipping after starting a GLP-1 are real experiences and deserve an honest explanation rather than dismissal. None of these is a demonstrated direct drug effect, but several are plausible and mostly transient, and they cluster in the early weeks and at dose escalations:

1. A deep caloric deficit and rapid energy loss. GLP-1 drugs work by sharply cutting intake. A body in an aggressive energy deficit is not primed for sexual interest, and the CALERIE 2 randomized trial of sustained calorie restriction in healthy adults (Martin 2016^[8]) showed the deficit itself — with no drug involved — can affect sexual function. This is the process, not the molecule.
2. Fatigue and low energy during titration. Nausea, reduced food intake, and the early GI burden sap energy. Low energy lowers libido and can make erections less reliable for ordinary, non-hormonal reasons. As the dose stabilizes and nausea settles, this typically eases.
3. Dehydration. Reduced intake plus any vomiting or diarrhea can leave you under-hydrated, and an erection is fundamentally a vascular event. Mild dehydration and the fatigue that comes with it can transiently blunt performance. (Dehydration-related acute kidney injury is a labeled GLP-1 caution — another reason to keep fluids up.)
4. Very rapid fat loss transiently shifting hormones. Hormonal adaptation to a fast, large energy deficit can be non-linear in the short term before the obesity-reversing, testosterone-raising trajectory (Corona 2013^[3], Camacho 2013^[7]) takes over. The long-run direction in men is up, but the first weeks can feel different.
5. The psychological load of a major body change. Rapidly changing how you look and eat, plus the stress of a big lifestyle shift, can affect desire and confidence. Body image usually improves as weight comes off, but the transition itself is a real, non-hormonal variable.

Directly caused by the drug vs. happens during weight loss

The single most useful distinction for anyone worried about this is between an effect the drug causes and an effect that co-occurs with the weight-loss phase the drug starts:

• Directly caused by the drug: no evidence. ED is not on any GLP-1 label, no pivotal trial flagged it, and there is no plausible receptor mechanism by which semaglutide or tirzepatide would impair the cavernosal vascular response.
• Can happen during a weight-loss phase: plausible and usually temporary — deep caloric deficit, fatigue, dehydration, short-term hormonal shifts, and the psychological load of change. These are tied to how weight loss happens, not to the molecule, and they tend to resolve as the body adapts.
• The long-run weight-loss effect: positive in obesity-driven ED. As body weight falls 10–15% or more, endothelial function recovers (Khoo 2014^[6]) and testosterone rises (Corona 2013^[3]), the same cascade that reversed ED in the Esposito^[1] and bariatric literature.

What to do if you notice ED on a GLP-1

1. Rule out other causes first. New ED is rarely about one new medication. Review everything else: blood pressure, blood sugar, cholesterol, other drugs (thiazides, beta-blockers, finasteride, and SSRIs are common culprits), alcohol, smoking, sleep apnea, and mood. A primary-care or urology evaluation is the right first step for any new or progressive ED.
2. Cover the basics that the weight-loss phase disrupts. Hydrate adequately, protect energy and lean mass with sufficient protein and resistance training, and prioritize sleep. Do not under-eat protein just because appetite is low — lean mass and energy support erectile function and testosterone.
3. Give the early phase time. If the dip tracks your worst nausea and fatigue and eases as the dose stabilizes, that is the most common and most self-limited scenario. Reassess after a dose has been stable for several weeks and weight loss is underway.
4. Talk to your prescriber. Do not stop the GLP-1 on your own to “test” it. Dose timing, anti-nausea support, hydration, and addressing a concurrent medication or mood issue often resolve the problem without giving up the weight-loss benefit. A PDE5 inhibitor (sildenafil, tadalafil) can be used during this period if appropriate — there is no pharmacokinetic interaction with the GLP-1 drugs.
5. Expect improvement as weight loss progresses. In obesity-driven ED, the documented trajectory is recovery, not decline, as meaningful weight comes off. If erectile function is still flat at month 6 despite ≥10% weight loss, that is a reason for a fuller workup (testosterone, vascular evaluation), not a reason to assume the drug caused it.

When ED is the warning sign, not the GLP-1

Erectile dysfunction is an established early marker of cardiovascular disease — often preceding a heart attack or stroke by years — because the penile arteries are small and show endothelial dysfunction before the coronary arteries do. The Thompson 2005 JAMA analysis of the Prostate Cancer Prevention Trial^[10] found that incident ED was associated with a significantly higher risk of subsequent cardiovascular events, a risk comparable to current smoking or a family history of myocardial infarction. The Vlachopoulos 2013 meta-analysis^[11] pooled prospective cohorts and confirmed that ED predicts cardiovascular events and all-cause mortality. The practical message: new ED in a man with obesity, diabetes, or other cardiovascular risk factors is a reason to assess heart health, not a side effect to wave away. Notably, the same GLP-1 driving weight loss is also reducing those cardiovascular risk factors — so the medication is far more likely to be protecting the vascular bed than harming it.

Bottom line

• There is no good evidence that Ozempic, Wegovy, Mounjaro, Zepbound, or any GLP-1 directly causes erectile dysfunction. ED is not a labeled adverse reaction for any of them, and the pivotal trials did not flag it.
• The stronger, evidence-backed direction is improvement: by driving large weight loss (STEP-1 −14.9%^[4], SURMOUNT-1 −20.9%^[5]), these drugs tend to restore erectile function in obesity-driven ED over months (Esposito 2004^[1], Khoo 2014^[6], Corona 2013^[3]).
• An early dip in erections or libido is plausible but usually transient and tied to the weight-loss process — deep caloric deficit, fatigue, dehydration, short-term hormonal shifts, and the psychological load of change — not a fixed drug effect (Martin 2016 CALERIE^[8]).
• If you notice ED on a GLP-1: rule out other causes, cover hydration/energy/sleep, give the early phase time, and talk to your prescriber. It often improves as weight loss progresses.
• New or progressive ED can be an early marker of cardiovascular disease (Thompson 2005^[10], Vlachopoulos 2013^[11]) — a reason for a proper workup, not an assumption that “it is just the Ozempic.”

Related research

• GLP-1 weight loss and ED reversal — the Esposito-to-bariatric magnitude review and what erectile improvement to expect
• GLP-1s and erectile dysfunction — the obesity, mechanism, and treatment-route overview
• GLP-1s and sex drive — the both-directions libido hub (why it can go up or down)
• Ozempic, testosterone, and male fertility — how GLP-1 weight loss moves the male hormonal axis
• Semaglutide and sex drive in women — the female libido spoke, including the PCOS-androgen question
• TRT, testosterone, and weight loss — when weight loss reverses low testosterone and when replacement is the right step

Important disclaimer. This article is educational and does not constitute medical advice. Erectile dysfunction is not a listed adverse reaction in the FDA prescribing information for Ozempic, Wegovy, Mounjaro, or Zepbound; statements about labeling are drawn from those documents (DailyMed). New or progressive erectile dysfunction can be an early marker of cardiovascular disease and warrants evaluation by a clinician, including a cardiovascular risk assessment, a morning total testosterone, a medication review, and a mood and sleep screen. Do not start, stop, or change any prescription medication based on this article. Every primary source cited here was verified against the live PubMed E-utilities API on 2026-06-24.

Last verified: 2026-06-24. Next review: every 12 months, or sooner if a GLP-1 trial reports an erectile-function signal or a label is updated.